|
Golimumab (CNTO 148) is a human monoclonal antibody which is used as an immunosuppressive drug and marketed under the brand name Simponi. Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule〔(Statement On A Nonproprietary Name Adopted By The USAN Council – Golimumab ), ''American Medical Association''.〕 and hence is a TNF inhibitor. Golimumab was developed by Centocor and is approved in Canada〔 Apr 2009〕 and the United States〔(FDA Approves Simponi )〕 as a once monthly subcutaneous treatment for adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Golimumab has been approved in 2013 for use in adults with moderately to severely active ulcerative colitis. In the same year, Johnson & Johnson, the parent company of Centocor, also received (an approval ) from European Medicines Agency (EMEA) for the use of golimumab as a treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.〔(Johnson & Johnson Reports 2008 First-Quarter Results )〕 Golimumab is marketed by Merck & Co, Inc. in Europe, pending final arbitration between J&J and Merck.〔(FDA approves Johnson & Johnson rheumatoid arthritis drug golimumab )〕〔() Merck sees fast ruling in J&J Remicade arbitration 〕〔(【引用サイトリンク】 title= Simponi European Public Assessment Report )〕 ==Clinical trials== 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Golimumab」の詳細全文を読む スポンサード リンク
|